Nivolumab plus chemotherapy prolongs PFS in gastric, gastroesophageal junction cancer

The addition of nivolumab to first-line chemotherapy significantly improved PFS, but not OS, for patients with advanced or recurrent HER2-negative gastric and gastroesophageal junction cancer, according to phase 3 study findings.
Results of the double-blind, randomized ATTRACTION-4 trial, presented at ESMO Virtual Congress 2020, also showed a higher objective response rate and more durable responses with the combination than with chemotherapy alone, researchers noted.
“Nivolumab [Opdivo, Bristol Myers Squibb] has shown significant survival benefit for heavily pretreated patients with

Source link

Related posts

Study ties unhealthy gums to liver cancer risk


Randomized Trial Supports Long-Term Safety of Proton-Pump Inhibitors


Management of Moderate-to-Severe Ulcerative Colitis


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World